Browsing Tag
AVA6103
21 posts
Avacta just won a clean FDA path to full AVA6000 approval, so why did $AVCT barely move?
Avacta won a clean FDA path to full AVA6000 approval, yet AVCT (AIM) barely moved. The real question is whether a partner signs before cash runs low.
Avacta targets late-2026 AVA6103 data as AVCT shifts from funding risk to clinical proof
Avacta Group has outlined a catalyst-heavy second half of 2026, with new AVA6000 data, the first AVA6103 clinical results and potential partnering decisions set to test the commercial value of its tumour-activated oncology platform.
Avacta Therapeutics (AIM: AVCT) names Richard Hughes chairman as Shaun Chilton steps back
Avacta hands the chair to dealmaker Richard Hughes and adds a biotech deputy, a boardroom rebuild aimed squarely at pharma partnering. Read more.
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.
Avacta FY25 puts AVCT on a clock: £16.9m cash, two Phase 1 reads, one shot
Avacta Group posts FY25 results with two clinical assets in trial, £16.9m cash, and AVA6103 data due in H2 2026 as AVCT trades near 52-week high.
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
Avacta Group (AIM: AVCT) delivers preCISION payload data that challenges Enhertu and Datroway tumor selectivity at Science Day 2026
Avacta is no longer pitching a platform. It is benchmarking preCISION directly against Enhertu and Datroway, and the tumor selectivity numbers matter.
AVCT stock near 52-week high as Avacta Group pre|CISION data challenges Enhertu benchmark at AACR 2026
Avacta Group (AIM: AVCT) AACR 2026 data show AVA6103 outperforms Enhertu on tumor selectivity while AVA6207 delivers first in vivo dual payload results. Read our analysis.
Avacta (AIM: AVCT): First patient dosed in FOCUS-01 with three data catalysts lined up across 2026
Avacta (AIM: AVCT) dosed the first FOCUS-01 patient in March 2026. Three catalysts follow: AACR April 21, AVA6000 H1 update, AVA6103 late H2 data. Full retail investor roadmap inside.
Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial
Avacta Therapeutics (AIM: AVCT) is presenting two posters at AACR 2026 in San Diego. Here is what investors need to understand about conference data versus clinical trial readouts and which milestones actually move the stock.